Abstract
Acquired drug resistance is one of the most important problems in cancer chemotherapy. One of the proposed mechanisms for these phenomena is the sequestration of alkylating agents by metallothionein in vivo. This research shows that metallothionein can covalently sequester phosphoramide mustard, the active form of cyclophosphamide in vitro. On-line electrospray mass spectrometry reveals that it is phosphoramide, not nornitrogen mustard that alkylates metallothionein, although the metallothionein/nornitrogen mustard adduct was isolated as the major adduct. Tandem mass spectrometric experiments were performed on an isolated drug-modified tryptic peptide. The alkylation occurred predominantly at Cys48 of metallothionein. These results provide further evidence that overexpression of metallothionein can detoxify the active form of the drugs.
Footnotes
-
Send reprint requests to: Dr. C. Fenselau, Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742. E-mail: smccain{at}umail.umd.edu
-
This work was supported by National Institutes of Heath Grant GM21248.
- Abbreviations used are::
- MT
- metallothionein
- CP
- cyclophosphamide
- ESI
- electrospray mass ionization
- FAB
- fast atom bombardment
- MALDI
- matrix-assisted laser desorption ionization
- MS
- mass spectrometry
- MeOH
- methanol
- MS/MS
- tandem mass spectrometry
- NNM
- nornitrogen mustard
- PM
- phosphoramide mustard
- RP
- reversed-phase
- TFA
- trifluoroacetic acid
- Received November 11, 1998.
- Accepted March 16, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|